| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| AMGN - Amgen Inc | BUY | 476 @ USD 315.59 | USD 150,221 | The ETF bought 476 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 315.59 compared to the previous average buy price of 286.598. This is 10.1% higher than average price of previous purchases of AMGN. |
| GILD - Guild Esports Plc | BUY | 1,213 @ USD 123.4 | USD 149,684 | The ETF bought 1213 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 123.4 compared to the previous average buy price of 112.464. This is 9.7% higher than average price of previous purchases of GILD. |
| VRTX - Vertex Pharmaceuticals Inc | BUY | 350 @ USD 416.25 | USD 145,688 | The ETF bought 350 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 416.25 compared to the previous average buy price of 414.932. This is 0.3% higher than average price of previous purchases of VRTX. |
| REGN - Regeneron Pharmaceuticals Inc | BUY | 171 @ USD 646.87 | USD 110,615 | The ETF bought 171 new shares of REGN (Regeneron Pharmaceuticals Inc). The shares were bought for an average price of 646.87 compared to the previous average buy price of 625.065. This is 3.5% higher than average price of previous purchases of REGN. |
| ALNY - Alnylam Pharmaceuticals Inc | BUY | 215 @ USD 440.49 | USD 94,705 | The ETF bought 215 new shares of ALNY (Alnylam Pharmaceuticals Inc). The shares were bought for an average price of 440.49 compared to the previous average buy price of 372.91. This is 18.1% higher than average price of previous purchases of ALNY. |
| AZN - AstraZeneca PLC | BUY | 857 @ USD 83.77 | USD 71,791 | The ETF bought 857 new shares of AZN (AstraZeneca PLC). The shares were bought for an average price of 83.77 compared to the previous average buy price of 74.3929. This is 12.6% higher than average price of previous purchases of AZN. |
| INSM - Insmed Inc | BUY | 350 @ USD 185.68 | USD 64,988 | The ETF bought 350 new shares of INSM (Insmed Inc). The shares were bought for an average price of 185.68 compared to the previous average buy price of 117.875. This is 57.5% higher than average price of previous purchases of INSM. |
| ARGX - argenx NV ADR | BUY | 51 @ USD 851.015 | USD 43,402 | The ETF bought 51 new shares of ARGX (argenx NV ADR). The shares were bought for an average price of 851.015 compared to the previous average buy price of 631.044. This is 34.9% higher than average price of previous purchases of ARGX. |
| BIIB - Biogen Inc | BUY | 243 @ USD 156.74 | USD 38,088 | The ETF bought 243 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 156.74 compared to the previous average buy price of 137.382. This is 14.1% higher than average price of previous purchases of BIIB. |
| INCY - Incyte Corporation | BUY | 324 @ USD 105.2 | USD 34,085 | The ETF bought 324 new shares of INCY (Incyte Corporation). The shares were bought for an average price of 105.2 compared to the previous average buy price of 73.2301. This is 43.7% higher than average price of previous purchases of INCY. |
| UTHR - United Therapeutics Corporation | BUY | 75 @ USD 454 | USD 34,050 | The ETF bought 75 new shares of UTHR (United Therapeutics Corporation). The shares were bought for an average price of 454 compared to the previous average buy price of 338.983. This is 33.9% higher than average price of previous purchases of UTHR. |
| ILMN - Illumina Inc | BUY | 254 @ USD 121.11 | USD 30,762 | The ETF bought 254 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 121.11 compared to the previous average buy price of 96.6282. This is 25.3% higher than average price of previous purchases of ILMN. |
| RPRX - Royalty Pharma Plc | BUY | 714 @ USD 40.78 | USD 29,117 | The ETF bought 714 new shares of RPRX (Royalty Pharma Plc). The shares were bought for an average price of 40.78 compared to the previous average buy price of 35.4267. This is 15.1% higher than average price of previous purchases of RPRX. |
| MEDP - Medpace Holdings Inc | BUY | 47 @ USD 592.19 | USD 27,833 | The ETF bought 47 new shares of MEDP (Medpace Holdings Inc). The shares were bought for an average price of 592.19 compared to the previous average buy price of 386.096. This is 53.4% higher than average price of previous purchases of MEDP. |
| NBIX - Neurocrine Biosciences Inc | BUY | 164 @ USD 154.8 | USD 25,387 | The ETF bought 164 new shares of NBIX (Neurocrine Biosciences Inc). The shares were bought for an average price of 154.8 compared to the previous average buy price of 129.315. This is 19.7% higher than average price of previous purchases of NBIX. |
| ROIV - Roivant Sciences Ltd | BUY | 1,128 @ USD 20.57 | USD 23,203 | The ETF bought 1128 new shares of ROIV (Roivant Sciences Ltd). The shares were bought for an average price of 20.57 compared to the previous average buy price of 12.6089. This is 63.1% higher than average price of previous purchases of ROIV. |
| SMMT - Summit Therapeutics PLC | BUY | 1,232 @ USD 18.45 | USD 22,730 | The ETF bought 1232 new shares of SMMT (Summit Therapeutics PLC). The shares were bought for an average price of 18.45 compared to the previous average buy price of 21.5764. This is -14.5% lower than average price of previous purchases of SMMT. |
| SNY - Sanofi ADR | BUY | 445 @ USD 49.49 | USD 22,023 | The ETF bought 445 new shares of SNY (Sanofi ADR). The shares were bought for an average price of 49.49 compared to the previous average buy price of 49.98. This is -1.0% lower than average price of previous purchases of SNY. |
| ASND - Ascendis Pharma AS | BUY | 101 @ USD 199.28 | USD 20,127 | The ETF bought 101 new shares of ASND (Ascendis Pharma AS). The shares were bought for an average price of 199.28 compared to the previous average buy price of 176.993. This is 12.6% higher than average price of previous purchases of ASND. |
| GH - Guardant Health Inc | BUY | 207 @ USD 96.25 | USD 19,924 | The ETF bought 207 new shares of GH (Guardant Health Inc). The shares were bought for an average price of 96.25 compared to the previous average buy price of 53.7878. This is 78.9% higher than average price of previous purchases of GH. |
| BBIO - BridgeBio Pharma Inc | BUY | 317 @ USD 62.73 | USD 19,885 | The ETF bought 317 new shares of BBIO (BridgeBio Pharma Inc). The shares were bought for an average price of 62.73 compared to the previous average buy price of 44.0653. This is 42.4% higher than average price of previous purchases of BBIO. |
| IONS - Ionis Pharmaceuticals Inc | BUY | 265 @ USD 74.1 | USD 19,637 | The ETF bought 265 new shares of IONS (Ionis Pharmaceuticals Inc). The shares were bought for an average price of 74.1 compared to the previous average buy price of 47.4239. This is 56.3% higher than average price of previous purchases of IONS. |
| VTRS - Viatris Inc | BUY | 1,935 @ USD 10.11 | USD 19,563 | The ETF bought 1935 new shares of VTRS (Viatris Inc). The shares were bought for an average price of 10.11 compared to the previous average buy price of 9.55132. This is 5.8% higher than average price of previous purchases of VTRS. |
| RVMD - Revolution Medicines Inc | BUY | 310 @ USD 61.38 | USD 19,028 | The ETF bought 310 new shares of RVMD (Revolution Medicines Inc). The shares were bought for an average price of 61.38 compared to the previous average buy price of 40.834. This is 50.3% higher than average price of previous purchases of RVMD. |
| EXEL - Exelixis Inc | BUY | 445 @ USD 40.8 | USD 18,156 | The ETF bought 445 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 40.8 compared to the previous average buy price of 40.8999. This is -0.2% lower than average price of previous purchases of EXEL. |
| MDGL - Madrigal Pharmaceuticals Inc | BUY | 37 @ USD 488.58 | USD 18,077 | The ETF bought 37 new shares of MDGL (Madrigal Pharmaceuticals Inc). The shares were bought for an average price of 488.58 compared to the previous average buy price of 342.071. This is 42.8% higher than average price of previous purchases of MDGL. |
| BNTX - BioNTech SE | BUY | 166 @ USD 103.35 | USD 17,156 | The ETF bought 166 new shares of BNTX (BioNTech SE). The shares were bought for an average price of 103.35 compared to the previous average buy price of 105.305. This is -1.9% lower than average price of previous purchases of BNTX. |
| BMRN - Biomarin Pharmaceutical Inc | BUY | 317 @ USD 51.84 | USD 16,433 | The ETF bought 317 new shares of BMRN (Biomarin Pharmaceutical Inc). The shares were bought for an average price of 51.84 compared to the previous average buy price of 58.3808. This is -11.2% lower than average price of previous purchases of BMRN. |
| MRNA - Moderna Inc | BUY | 643 @ USD 24.33 | USD 15,644 | The ETF bought 643 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 24.33 compared to the previous average buy price of 29.378. This is -17.2% lower than average price of previous purchases of MRNA. |
| RNA - Avidity Biosciences Inc | BUY | 213 @ USD 69.78 | USD 14,863 | The ETF bought 213 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 69.78 compared to the previous average buy price of 36.0618. This is 93.5% higher than average price of previous purchases of RNA. |
| JAZZ - Jazz Pharmaceuticals PLC | BUY | 100 @ USD 134.05 | USD 13,405 | The ETF bought 100 new shares of JAZZ (Jazz Pharmaceuticals PLC). The shares were bought for an average price of 134.05 compared to the previous average buy price of 121.217. This is 10.6% higher than average price of previous purchases of JAZZ. |
| HALO - Halozyme Therapeutics Inc | BUY | 193 @ USD 68.39 | USD 13,199 | The ETF bought 193 new shares of HALO (Halozyme Therapeutics Inc). The shares were bought for an average price of 68.39 compared to the previous average buy price of 59.2753. This is 15.4% higher than average price of previous purchases of HALO. |
| CYTK - Cytokinetics Inc | BUY | 198 @ USD 60.3 | USD 11,939 | The ETF bought 198 new shares of CYTK (Cytokinetics Inc). The shares were bought for an average price of 60.3 compared to the previous average buy price of 42.0909. This is 43.3% higher than average price of previous purchases of CYTK. |
| MRUS - Merus BV | BUY | 125 @ USD 95.16 | USD 11,895 | The ETF bought 125 new shares of MRUS (Merus BV). The shares were bought for an average price of 95.16 compared to the previous average buy price of 63.0714. This is 50.9% higher than average price of previous purchases of MRUS. |
| AXSM - Axsome Therapeutics Inc | BUY | 82 @ USD 139.41 | USD 11,432 | The ETF bought 82 new shares of AXSM (Axsome Therapeutics Inc). The shares were bought for an average price of 139.41 compared to the previous average buy price of 113.769. This is 22.5% higher than average price of previous purchases of AXSM. |
| RYTM - Rhythm Pharmaceuticals Inc | BUY | 110 @ USD 98.49 | USD 10,834 | The ETF bought 110 new shares of RYTM (Rhythm Pharmaceuticals Inc). The shares were bought for an average price of 98.49 compared to the previous average buy price of 74.8725. This is 31.5% higher than average price of previous purchases of RYTM. |
| NUVL - Nuvalent Inc | BUY | 110 @ USD 95.87 | USD 10,546 | The ETF bought 110 new shares of NUVL (Nuvalent Inc). The shares were bought for an average price of 95.87 compared to the previous average buy price of 81.5546. This is 17.6% higher than average price of previous purchases of NUVL. |
| KRYS - Krystal Biotech Inc | BUY | 48 @ USD 199.97 | USD 9,599 | The ETF bought 48 new shares of KRYS (Krystal Biotech Inc). The shares were bought for an average price of 199.97 compared to the previous average buy price of 159.295. This is 25.5% higher than average price of previous purchases of KRYS. |
| PTCT - PTC Therapeutics Inc | BUY | 132 @ USD 72.59 | USD 9,582 | The ETF bought 132 new shares of PTCT (PTC Therapeutics Inc). The shares were bought for an average price of 72.59 compared to the previous average buy price of 54.2091. This is 33.9% higher than average price of previous purchases of PTCT. |
| ARWR - Arrowhead Pharmaceuticals Inc | BUY | 229 @ USD 39.6 | USD 9,068 | The ETF bought 229 new shares of ARWR (Arrowhead Pharmaceuticals Inc). The shares were bought for an average price of 39.6 compared to the previous average buy price of 20.7027. This is 91.3% higher than average price of previous purchases of ARWR. |
| PCVX - Vaxcyte Inc | BUY | 215 @ USD 41.71 | USD 8,968 | The ETF bought 215 new shares of PCVX (Vaxcyte Inc). The shares were bought for an average price of 41.71 compared to the previous average buy price of 44.3939. This is -6.0% lower than average price of previous purchases of PCVX. |
| ALKS - Alkermes Plc | BUY | 273 @ USD 31.68 | USD 8,649 | The ETF bought 273 new shares of ALKS (Alkermes Plc). The shares were bought for an average price of 31.68 compared to the previous average buy price of 30.3896. This is 4.2% higher than average price of previous purchases of ALKS. |
| CRSP - Crispr Therapeutics AG | BUY | 150 @ USD 56.61 | USD 8,492 | The ETF bought 150 new shares of CRSP (Crispr Therapeutics AG). The shares were bought for an average price of 56.61 compared to the previous average buy price of 52.493. This is 7.8% higher than average price of previous purchases of CRSP. |
| PTGX - Protagonist Therapeutics Inc | BUY | 103 @ USD 79.78 | USD 8,217 | The ETF bought 103 new shares of PTGX (Protagonist Therapeutics Inc). The shares were bought for an average price of 79.78 compared to the previous average buy price of 55.7643. This is 43.1% higher than average price of previous purchases of PTGX. |
| ACLX - Arcellx Inc | BUY | 92 @ USD 88.2 | USD 8,114 | The ETF bought 92 new shares of ACLX (Arcellx Inc). The shares were bought for an average price of 88.2 compared to the previous average buy price of 71.5433. This is 23.3% higher than average price of previous purchases of ACLX. |
| KYMR - Kymera Therapeutics Inc | BUY | 119 @ USD 61 | USD 7,259 | The ETF bought 119 new shares of KYMR (Kymera Therapeutics Inc). The shares were bought for an average price of 61 compared to the previous average buy price of 46.0961. This is 32.3% higher than average price of previous purchases of KYMR. |
| AKRO - Akero Therapeutics Inc | BUY | 133 @ USD 53.91 | USD 7,170 | The ETF bought 133 new shares of AKRO (Akero Therapeutics Inc). The shares were bought for an average price of 53.91 compared to the previous average buy price of 49.1339. This is 9.7% higher than average price of previous purchases of AKRO. |
| IMVT - Immunovant Inc | BUY | 291 @ USD 23.67 | USD 6,888 | The ETF bought 291 new shares of IMVT (Immunovant Inc). The shares were bought for an average price of 23.67 compared to the previous average buy price of 17.8723. This is 32.4% higher than average price of previous purchases of IMVT. |
| LGND - Ligand Pharmaceuticals Incorporated | BUY | 33 @ USD 208.22 | USD 6,871 | The ETF bought 33 new shares of LGND (Ligand Pharmaceuticals Incorporated). The shares were bought for an average price of 208.22 compared to the previous average buy price of 130.735. This is 59.3% higher than average price of previous purchases of LGND. |
| CRNX - Crinetics Pharmaceuticals Inc | BUY | 156 @ USD 43.49 | USD 6,784 | The ETF bought 156 new shares of CRNX (Crinetics Pharmaceuticals Inc). The shares were bought for an average price of 43.49 compared to the previous average buy price of 34.6699. This is 25.4% higher than average price of previous purchases of CRNX. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | BUY | 525 @ USD 11.66 | USD 6,122 | The ETF bought 525 new shares of AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock). The shares were bought for an average price of 11.66 compared to the previous average buy price of 8.7227. This is 33.7% higher than average price of previous purchases of AMRX. |
| ACAD - ACADIA Pharmaceuticals Inc | BUY | 281 @ USD 21.65 | USD 6,084 | The ETF bought 281 new shares of ACAD (ACADIA Pharmaceuticals Inc). The shares were bought for an average price of 21.65 compared to the previous average buy price of 20.789. This is 4.1% higher than average price of previous purchases of ACAD. |
| PRAX - Praxis Precision Medicines Inc | BUY | 35 @ USD 172.35 | USD 6,032 | The ETF bought 35 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 172.35 compared to the previous average buy price of 59.5523. This is 189.4% higher than average price of previous purchases of PRAX. |
| MIRM - Mirum Pharmaceuticals Inc | BUY | 84 @ USD 67.72 | USD 5,688 | The ETF bought 84 new shares of MIRM (Mirum Pharmaceuticals Inc). The shares were bought for an average price of 67.72 compared to the previous average buy price of 55.0024. This is 23.1% higher than average price of previous purchases of MIRM. |
| ADMA - ADMA Biologics Inc | BUY | 398 @ USD 14.03 | USD 5,584 | The ETF bought 398 new shares of ADMA (ADMA Biologics Inc). The shares were bought for an average price of 14.03 compared to the previous average buy price of 17.4539. This is -19.6% lower than average price of previous purchases of ADMA. |
| VCYT - Veracyte Inc | BUY | 132 @ USD 41.69 | USD 5,503 | The ETF bought 132 new shares of VCYT (Veracyte Inc). The shares were bought for an average price of 41.69 compared to the previous average buy price of 30.8591. This is 35.1% higher than average price of previous purchases of VCYT. |
| IRON - Ironveld Plc | BUY | 58 @ USD 87 | USD 5,046 | The ETF bought 58 new shares of IRON (Ironveld Plc). The shares were bought for an average price of 87 compared to the previous average buy price of 58.2514. This is 49.4% higher than average price of previous purchases of IRON. |
| CGON - CG Oncology, Inc. Common stock | BUY | 127 @ USD 39.69 | USD 5,041 | The ETF bought 127 new shares of CGON (CG Oncology, Inc. Common stock). The shares were bought for an average price of 39.69 compared to the previous average buy price of 29.6278. This is 34.0% higher than average price of previous purchases of CGON. |
| RARE - Ultragenyx | BUY | 161 @ USD 30.95 | USD 4,983 | The ETF bought 161 new shares of RARE (Ultragenyx). The shares were bought for an average price of 30.95 compared to the previous average buy price of 36.4002. This is -15.0% lower than average price of previous purchases of RARE. |
| RARE - WISETFWTMRARETFP | BUY | 161 @ USD 30.95 | USD 4,983 | The ETF bought 161 new shares of RARE (WISETFWTMRARETFP). The shares were bought for an average price of 30.95 compared to the previous average buy price of 36.4002. This is -15.0% lower than average price of previous purchases of RARE. |
| ARQT - Arcutis Biotherapeutics Inc | BUY | 197 @ USD 25.1 | USD 4,945 | The ETF bought 197 new shares of ARQT (Arcutis Biotherapeutics Inc). The shares were bought for an average price of 25.1 compared to the previous average buy price of 15.9437. This is 57.4% higher than average price of previous purchases of ARQT. |
| XENE - Xenon Pharmaceuticals Inc | BUY | 129 @ USD 38.3 | USD 4,941 | The ETF bought 129 new shares of XENE (Xenon Pharmaceuticals Inc). The shares were bought for an average price of 38.3 compared to the previous average buy price of 35.3894. This is 8.2% higher than average price of previous purchases of XENE. |
| TVTX - Travere Therapeutics Inc | BUY | 146 @ USD 33.3 | USD 4,862 | The ETF bought 146 new shares of TVTX (Travere Therapeutics Inc). The shares were bought for an average price of 33.3 compared to the previous average buy price of 19.3242. This is 72.3% higher than average price of previous purchases of TVTX. |
| GRAL - GRAIL, LLC | BUY | 60 @ USD 80.06 | USD 4,804 | The ETF bought 60 new shares of GRAL (GRAIL, LLC). The shares were bought for an average price of 80.06 compared to the previous average buy price of 51.4862. This is 55.5% higher than average price of previous purchases of GRAL. |
| TARS - Tarsus Pharmaceuticals Inc | BUY | 70 @ USD 68.09 | USD 4,766 | The ETF bought 70 new shares of TARS (Tarsus Pharmaceuticals Inc). The shares were bought for an average price of 68.09 compared to the previous average buy price of 48.3869. This is 40.7% higher than average price of previous purchases of TARS. |
| SRRK - Scholar Rock Holding Corp | BUY | 160 @ USD 28.8 | USD 4,608 | The ETF bought 160 new shares of SRRK (Scholar Rock Holding Corp). The shares were bought for an average price of 28.8 compared to the previous average buy price of 35.0637. This is -17.9% lower than average price of previous purchases of SRRK. |
| FOLD - Amicus Therapeutics Inc | BUY | 507 @ USD 8.9 | USD 4,512 | The ETF bought 507 new shares of FOLD (Amicus Therapeutics Inc). The shares were bought for an average price of 8.9 compared to the previous average buy price of 7.29317. This is 22.0% higher than average price of previous purchases of FOLD. |
| LEGN - Legend Biotech Corp | BUY | 139 @ USD 32.37 | USD 4,499 | The ETF bought 139 new shares of LEGN (Legend Biotech Corp). The shares were bought for an average price of 32.37 compared to the previous average buy price of 34.8994. This is -7.2% lower than average price of previous purchases of LEGN. |
| SUPN - Supernus Pharmaceuticals Inc | BUY | 94 @ USD 47.265 | USD 4,443 | The ETF bought 94 new shares of SUPN (Supernus Pharmaceuticals Inc). The shares were bought for an average price of 47.265 compared to the previous average buy price of 37.1482. This is 27.2% higher than average price of previous purchases of SUPN. |
| IDYA - Ideaya Biosciences Inc | BUY | 147 @ USD 29.85 | USD 4,388 | The ETF bought 147 new shares of IDYA (Ideaya Biosciences Inc). The shares were bought for an average price of 29.85 compared to the previous average buy price of 23.1053. This is 29.2% higher than average price of previous purchases of IDYA. |
| DYN - Dyne Therapeutics Inc | BUY | 237 @ USD 18.205 | USD 4,315 | The ETF bought 237 new shares of DYN (Dyne Therapeutics Inc). The shares were bought for an average price of 18.205 compared to the previous average buy price of 12.7136. This is 43.2% higher than average price of previous purchases of DYN. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | BUY | 237 @ USD 18.205 | USD 4,315 | The ETF bought 237 new shares of DYN (DYNAGREEN EN.PR.GR.H YC 1). The shares were bought for an average price of 18.205 compared to the previous average buy price of 12.7136. This is 43.2% higher than average price of previous purchases of DYN. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 76 @ USD 54.995 | USD 4,180 | The ETF bought 76 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 54.995 compared to the previous average buy price of 43.2087. This is 27.3% higher than average price of previous purchases of APGE. |
| APLS - Apellis Pharmaceuticals Inc | BUY | 211 @ USD 19.71 | USD 4,159 | The ETF bought 211 new shares of APLS (Apellis Pharmaceuticals Inc). The shares were bought for an average price of 19.71 compared to the previous average buy price of 21.0274. This is -6.3% lower than average price of previous purchases of APLS. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | BUY | 109 @ USD 37.01 | USD 4,034 | The ETF bought 109 new shares of MLYS (Mineralys Therapeutics, Inc. Common Stock). The shares were bought for an average price of 37.01 compared to the previous average buy price of 19.2083. This is 92.7% higher than average price of previous purchases of MLYS. |
| ADPT - Adaptive Biotechnologies Corp | BUY | 250 @ USD 15.56 | USD 3,890 | The ETF bought 250 new shares of ADPT (Adaptive Biotechnologies Corp). The shares were bought for an average price of 15.56 compared to the previous average buy price of 11.7695. This is 32.2% higher than average price of previous purchases of ADPT. |
| BEAM - Beam Therapeutics Inc | BUY | 166 @ USD 23.15 | USD 3,843 | The ETF bought 166 new shares of BEAM (Beam Therapeutics Inc). The shares were bought for an average price of 23.15 compared to the previous average buy price of 20.5607. This is 12.6% higher than average price of previous purchases of BEAM. |
| AGIO - Agios Pharm | BUY | 95 @ USD 40.31 | USD 3,829 | The ETF bought 95 new shares of AGIO (Agios Pharm). The shares were bought for an average price of 40.31 compared to the previous average buy price of 35.794. This is 12.6% higher than average price of previous purchases of AGIO. |
| CNTA - Centessa Pharmaceuticals PLC ADR | BUY | 158 @ USD 22.835 | USD 3,608 | The ETF bought 158 new shares of CNTA (Centessa Pharmaceuticals PLC ADR). The shares were bought for an average price of 22.835 compared to the previous average buy price of 16.3074. This is 40.0% higher than average price of previous purchases of CNTA. |
| DNLI - Denali Therapeutics Inc | BUY | 240 @ USD 14.41 | USD 3,458 | The ETF bought 240 new shares of DNLI (Denali Therapeutics Inc). The shares were bought for an average price of 14.41 compared to the previous average buy price of 15.0851. This is -4.5% lower than average price of previous purchases of DNLI. |
| COGT - Cogent Biosciences Inc | BUY | 230 @ USD 14.72 | USD 3,386 | The ETF bought 230 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 14.72 compared to the previous average buy price of 10.6212. This is 38.6% higher than average price of previous purchases of COGT. |
| IBRX - Immunitybio Inc | BUY | 1,580 @ USD 2.12 | USD 3,350 | The ETF bought 1580 new shares of IBRX (Immunitybio Inc). The shares were bought for an average price of 2.12 compared to the previous average buy price of 2.77213. This is -23.5% lower than average price of previous purchases of IBRX. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 716 @ USD 4.62 | USD 3,308 | The ETF bought 716 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 4.62 compared to the previous average buy price of 5.81039. This is -20.5% lower than average price of previous purchases of RXRX. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | BUY | 98 @ USD 33.47 | USD 3,280 | The ETF bought 98 new shares of GPCR (Structure Therapeutics Inc. American Depositary Shares). The shares were bought for an average price of 33.47 compared to the previous average buy price of 22.6606. This is 47.7% higher than average price of previous purchases of GPCR. |
| ANIP - ANI Pharmaceuticals Inc | BUY | 36 @ USD 90.23 | USD 3,248 | The ETF bought 36 new shares of ANIP (ANI Pharmaceuticals Inc). The shares were bought for an average price of 90.23 compared to the previous average buy price of 71.3477. This is 26.5% higher than average price of previous purchases of ANIP. |
| VCEL - Vericel Corp Ord | BUY | 83 @ USD 38.75 | USD 3,216 | The ETF bought 83 new shares of VCEL (Vericel Corp Ord). The shares were bought for an average price of 38.75 compared to the previous average buy price of 40.7916. This is -5.0% lower than average price of previous purchases of VCEL. |
| OCUL - Ocular Therapeutix Inc | BUY | 286 @ USD 10.63 | USD 3,040 | The ETF bought 286 new shares of OCUL (Ocular Therapeutix Inc). The shares were bought for an average price of 10.63 compared to the previous average buy price of 9.9428. This is 6.9% higher than average price of previous purchases of OCUL. |
| TWST - Twist Bioscience Corp | BUY | 99 @ USD 30.63 | USD 3,032 | The ETF bought 99 new shares of TWST (Twist Bioscience Corp). The shares were bought for an average price of 30.63 compared to the previous average buy price of 36.4647. This is -16.0% lower than average price of previous purchases of TWST. |
| AUPH - Aurinia Pharmaceuticals Inc | BUY | 217 @ USD 13.95 | USD 3,027 | The ETF bought 217 new shares of AUPH (Aurinia Pharmaceuticals Inc). The shares were bought for an average price of 13.95 compared to the previous average buy price of 8.93429. This is 56.1% higher than average price of previous purchases of AUPH. |
| AVDL - Avadel Pharmaceuticals PLC | BUY | 160 @ USD 18.71 | USD 2,994 | The ETF bought 160 new shares of AVDL (Avadel Pharmaceuticals PLC). The shares were bought for an average price of 18.71 compared to the previous average buy price of 10.6913. This is 75.0% higher than average price of previous purchases of AVDL. |
| EWTX - Edgewise Therapeutics Inc | BUY | 173 @ USD 17.09 | USD 2,957 | The ETF bought 173 new shares of EWTX (Edgewise Therapeutics Inc). The shares were bought for an average price of 17.09 compared to the previous average buy price of 15.7431. This is 8.6% higher than average price of previous purchases of EWTX. |
| HRMY - Harmony Biosciences Holdings | BUY | 94 @ USD 30.94 | USD 2,908 | The ETF bought 94 new shares of HRMY (Harmony Biosciences Holdings). The shares were bought for an average price of 30.94 compared to the previous average buy price of 31.8317. This is -2.8% lower than average price of previous purchases of HRMY. |
| MNKD - MannKind Corp | BUY | 506 @ USD 5.7 | USD 2,884 | The ETF bought 506 new shares of MNKD (MannKind Corp). The shares were bought for an average price of 5.7 compared to the previous average buy price of 4.70442. This is 21.2% higher than average price of previous purchases of MNKD. |
| SRPT - Sarepta Therapeutics Inc | BUY | 161 @ USD 17.64 | USD 2,840 | The ETF bought 161 new shares of SRPT (Sarepta Therapeutics Inc). The shares were bought for an average price of 17.64 compared to the previous average buy price of 34.4348. This is -48.8% lower than average price of previous purchases of SRPT. |
| JANX - Janux Therapeutics Inc | BUY | 99 @ USD 28.66 | USD 2,837 | The ETF bought 99 new shares of JANX (Janux Therapeutics Inc). The shares were bought for an average price of 28.66 compared to the previous average buy price of 27.66. This is 3.6% higher than average price of previous purchases of JANX. |
| KNSA - Kiniksa Pharmaceuticals Ltd | BUY | 72 @ USD 38.63 | USD 2,781 | The ETF bought 72 new shares of KNSA (Kiniksa Pharmaceuticals Ltd). The shares were bought for an average price of 38.63 compared to the previous average buy price of 29.4305. This is 31.3% higher than average price of previous purchases of KNSA. |
| VERA - Vera Therapeutics Inc | BUY | 105 @ USD 25.22 | USD 2,648 | The ETF bought 105 new shares of VERA (Vera Therapeutics Inc). The shares were bought for an average price of 25.22 compared to the previous average buy price of 26.751. This is -5.7% lower than average price of previous purchases of VERA. |
| TERN - Tern Plc | BUY | 144 @ USD 18.25 | USD 2,628 | The ETF bought 144 new shares of TERN (Tern Plc). The shares were bought for an average price of 18.25 compared to the previous average buy price of 5.19238. This is 251.5% higher than average price of previous purchases of TERN. |
| QURE - Uniqure NV | BUY | 91 @ USD 27.51 | USD 2,503 | The ETF bought 91 new shares of QURE (Uniqure NV). The shares were bought for an average price of 27.51 compared to the previous average buy price of 22.8064. This is 20.6% higher than average price of previous purchases of QURE. |
| TXG - 10X Genomics Inc | BUY | 191 @ USD 13 | USD 2,483 | The ETF bought 191 new shares of TXG (10X Genomics Inc). The shares were bought for an average price of 13 compared to the previous average buy price of 12.0295. This is 8.1% higher than average price of previous purchases of TXG. |
| TXG - Terex Corporation | BUY | 191 @ USD 13 | USD 2,483 | The ETF bought 191 new shares of TXG (Terex Corporation). The shares were bought for an average price of 13 compared to the previous average buy price of 12.0295. This is 8.1% higher than average price of previous purchases of TXG. |
| BCRX - BioCryst Pharmaceuticals Inc | BUY | 346 @ USD 7.03 | USD 2,432 | The ETF bought 346 new shares of BCRX (BioCryst Pharmaceuticals Inc). The shares were bought for an average price of 7.03 compared to the previous average buy price of 8.33473. This is -15.7% lower than average price of previous purchases of BCRX. |
| ZYME - Zymeworks Inc. Common Stock | BUY | 127 @ USD 17.9 | USD 2,273 | The ETF bought 127 new shares of ZYME (Zymeworks Inc. Common Stock). The shares were bought for an average price of 17.9 compared to the previous average buy price of 14.1821. This is 26.2% higher than average price of previous purchases of ZYME. |
| ARDX - Ardelyx Inc | BUY | 398 @ USD 5.65 | USD 2,249 | The ETF bought 398 new shares of ARDX (Ardelyx Inc). The shares were bought for an average price of 5.65 compared to the previous average buy price of 4.58993. This is 23.1% higher than average price of previous purchases of ARDX. |
| ABCL - Abcellera Biologics Inc | BUY | 494 @ USD 4.53 | USD 2,238 | The ETF bought 494 new shares of ABCL (Abcellera Biologics Inc). The shares were bought for an average price of 4.53 compared to the previous average buy price of 3.9221. This is 15.5% higher than average price of previous purchases of ABCL. |
| SYRE - Spyre Therapeutics Inc. | BUY | 99 @ USD 22.39 | USD 2,217 | The ETF bought 99 new shares of SYRE (Spyre Therapeutics Inc.). The shares were bought for an average price of 22.39 compared to the previous average buy price of 17.3459. This is 29.1% higher than average price of previous purchases of SYRE. |
| NTLA - Intellia Therapeutics Inc | BUY | 179 @ USD 12.32 | USD 2,205 | The ETF bought 179 new shares of NTLA (Intellia Therapeutics Inc). The shares were bought for an average price of 12.32 compared to the previous average buy price of 12.5347. This is -1.7% lower than average price of previous purchases of NTLA. |
| IMCR - Immunocore Holdings Ltd | BUY | 68 @ USD 31.595 | USD 2,148 | The ETF bought 68 new shares of IMCR (Immunocore Holdings Ltd). The shares were bought for an average price of 31.595 compared to the previous average buy price of 32.6522. This is -3.2% lower than average price of previous purchases of IMCR. |
| DVAX - Dynavax Technologies Corporation | BUY | 194 @ USD 10.99 | USD 2,132 | The ETF bought 194 new shares of DVAX (Dynavax Technologies Corporation). The shares were bought for an average price of 10.99 compared to the previous average buy price of 10.4605. This is 5.1% higher than average price of previous purchases of DVAX. |
| INVA - Innoviva Inc | BUY | 103 @ USD 20.58 | USD 2,120 | The ETF bought 103 new shares of INVA (Innoviva Inc). The shares were bought for an average price of 20.58 compared to the previous average buy price of 18.8301. This is 9.3% higher than average price of previous purchases of INVA. |
| WVE - Wave Life Sciences Ltd | BUY | 269 @ USD 7.88 | USD 2,120 | The ETF bought 269 new shares of WVE (Wave Life Sciences Ltd). The shares were bought for an average price of 7.88 compared to the previous average buy price of 8.46109. This is -6.9% lower than average price of previous purchases of WVE. |
| COLL - Collegium Pharmaceutical Inc | BUY | 52 @ USD 40.66 | USD 2,114 | The ETF bought 52 new shares of COLL (Collegium Pharmaceutical Inc). The shares were bought for an average price of 40.66 compared to the previous average buy price of 31.3238. This is 29.8% higher than average price of previous purchases of COLL. |
| HROW - Harrow Health Inc | BUY | 61 @ USD 34.44 | USD 2,101 | The ETF bought 61 new shares of HROW (Harrow Health Inc). The shares were bought for an average price of 34.44 compared to the previous average buy price of 33.2308. This is 3.6% higher than average price of previous purchases of HROW. |
| SNDX - Syndax Pharmaceuticals Inc | BUY | 142 @ USD 14.69 | USD 2,086 | The ETF bought 142 new shares of SNDX (Syndax Pharmaceuticals Inc). The shares were bought for an average price of 14.69 compared to the previous average buy price of 11.5137. This is 27.6% higher than average price of previous purchases of SNDX. |
| NVCR - Novocure Ltd | BUY | 184 @ USD 11.27 | USD 2,074 | The ETF bought 184 new shares of NVCR (Novocure Ltd). The shares were bought for an average price of 11.27 compared to the previous average buy price of 16.8363. This is -33.1% lower than average price of previous purchases of NVCR. |
| STOK - Stoke Therapeutics Inc | BUY | 92 @ USD 22.47 | USD 2,067 | The ETF bought 92 new shares of STOK (Stoke Therapeutics Inc). The shares were bought for an average price of 22.47 compared to the previous average buy price of 15.4471. This is 45.5% higher than average price of previous purchases of STOK. |
| NVAX - Novavax Inc | BUY | 268 @ USD 7.59 | USD 2,034 | The ETF bought 268 new shares of NVAX (Novavax Inc). The shares were bought for an average price of 7.59 compared to the previous average buy price of 7.38325. This is 2.8% higher than average price of previous purchases of NVAX. |
| NVAX - Hana Microelectronics Public Company Limited | BUY | 268 @ USD 7.59 | USD 2,034 | The ETF bought 268 new shares of NVAX (Hana Microelectronics Public Company Limited). The shares were bought for an average price of 7.59 compared to the previous average buy price of 7.38325. This is 2.8% higher than average price of previous purchases of NVAX. |
| ORIC - Oric Pharmaceuticals Inc | BUY | 160 @ USD 12.55 | USD 2,008 | The ETF bought 160 new shares of ORIC (Oric Pharmaceuticals Inc). The shares were bought for an average price of 12.55 compared to the previous average buy price of 10.4579. This is 20.0% higher than average price of previous purchases of ORIC. |
| GMAB - Genmab AS | BUY | 69 @ USD 28.84 | USD 1,990 | The ETF bought 69 new shares of GMAB (Genmab AS). The shares were bought for an average price of 28.84 compared to the previous average buy price of 23.2283. This is 24.2% higher than average price of previous purchases of GMAB. |
| PGEN - Precigen Inc | BUY | 504 @ USD 3.92 | USD 1,976 | The ETF bought 504 new shares of PGEN (Precigen Inc). The shares were bought for an average price of 3.92 compared to the previous average buy price of 2.21859. This is 76.7% higher than average price of previous purchases of PGEN. |
| CVAC - CureVac NV | BUY | 372 @ USD 5.25 | USD 1,953 | The ETF bought 372 new shares of CVAC (CureVac NV). The shares were bought for an average price of 5.25 compared to the previous average buy price of 4.83111. This is 8.7% higher than average price of previous purchases of CVAC. |
| RLAY - Relay Therapeutics Inc | BUY | 285 @ USD 6.53 | USD 1,861 | The ETF bought 285 new shares of RLAY (Relay Therapeutics Inc). The shares were bought for an average price of 6.53 compared to the previous average buy price of 4.10398. This is 59.1% higher than average price of previous purchases of RLAY. |
| AMPH - Amphastar P | BUY | 76 @ USD 24.23 | USD 1,841 | The ETF bought 76 new shares of AMPH (Amphastar P). The shares were bought for an average price of 24.23 compared to the previous average buy price of 25.4428. This is -4.8% lower than average price of previous purchases of AMPH. |
| AMLX - Amylyx Pharmaceuticals Inc | BUY | 147 @ USD 12.46 | USD 1,832 | The ETF bought 147 new shares of AMLX (Amylyx Pharmaceuticals Inc). The shares were bought for an average price of 12.46 compared to the previous average buy price of 6.81287. This is 82.9% higher than average price of previous purchases of AMLX. |
| ZLAB - Zai Lab Ltd | BUY | 79 @ USD 23.15 | USD 1,829 | The ETF bought 79 new shares of ZLAB (Zai Lab Ltd). The shares were bought for an average price of 23.15 compared to the previous average buy price of 34.2542. This is -32.4% lower than average price of previous purchases of ZLAB. |
| ELVN - Enliven Therapeutics Inc. | BUY | 98 @ USD 18.3 | USD 1,793 | The ETF bought 98 new shares of ELVN (Enliven Therapeutics Inc.). The shares were bought for an average price of 18.3 compared to the previous average buy price of 20.3815. This is -10.2% lower than average price of previous purchases of ELVN. |
| TSHA - Taysha Gene Therapies Inc | BUY | 452 @ USD 3.92 | USD 1,772 | The ETF bought 452 new shares of TSHA (Taysha Gene Therapies Inc). The shares were bought for an average price of 3.92 compared to the previous average buy price of 2.8472. This is 37.7% higher than average price of previous purchases of TSHA. |
| SANA - Sana Biotechnology Inc | BUY | 435 @ USD 4.05 | USD 1,762 | The ETF bought 435 new shares of SANA (Sana Biotechnology Inc). The shares were bought for an average price of 4.05 compared to the previous average buy price of 3.20526. This is 26.4% higher than average price of previous purchases of SANA. |
| ANAB - AnaptysBio Inc | BUY | 46 @ USD 38.2 | USD 1,757 | The ETF bought 46 new shares of ANAB (AnaptysBio Inc). The shares were bought for an average price of 38.2 compared to the previous average buy price of 23.8059. This is 60.5% higher than average price of previous purchases of ANAB. |
| GRFS - Grifols SA ADR | BUY | 202 @ USD 8.36 | USD 1,689 | The ETF bought 202 new shares of GRFS (Grifols SA ADR). The shares were bought for an average price of 8.36 compared to the previous average buy price of 9.46772. This is -11.7% lower than average price of previous purchases of GRFS. |
| NRIX - Nurix Therapeutics Inc | BUY | 133 @ USD 12.52 | USD 1,665 | The ETF bought 133 new shares of NRIX (Nurix Therapeutics Inc). The shares were bought for an average price of 12.52 compared to the previous average buy price of 12.0495. This is 3.9% higher than average price of previous purchases of NRIX. |
| FTRE - Fortrea Holdings Inc. | BUY | 150 @ USD 11.02 | USD 1,653 | The ETF bought 150 new shares of FTRE (Fortrea Holdings Inc.). The shares were bought for an average price of 11.02 compared to the previous average buy price of 6.48679. This is 69.9% higher than average price of previous purchases of FTRE. |
| XNCR - Xencor Inc | BUY | 118 @ USD 14 | USD 1,652 | The ETF bought 118 new shares of XNCR (Xencor Inc). The shares were bought for an average price of 14 compared to the previous average buy price of 11.0407. This is 26.8% higher than average price of previous purchases of XNCR. |
| CSTL - Castle Biosciences Inc | BUY | 48 @ USD 33.55 | USD 1,610 | The ETF bought 48 new shares of CSTL (Castle Biosciences Inc). The shares were bought for an average price of 33.55 compared to the previous average buy price of 21.2407. This is 58.0% higher than average price of previous purchases of CSTL. |
| PHAT - Phathom Pharmaceuticals Inc | BUY | 120 @ USD 13.04 | USD 1,565 | The ETF bought 120 new shares of PHAT (Phathom Pharmaceuticals Inc). The shares were bought for an average price of 13.04 compared to the previous average buy price of 8.82872. This is 47.7% higher than average price of previous purchases of PHAT. |
| PCRX - Pacira BioSciences, Inc. | BUY | 74 @ USD 21.1 | USD 1,561 | The ETF bought 74 new shares of PCRX (Pacira BioSciences, Inc.). The shares were bought for an average price of 21.1 compared to the previous average buy price of 23.7962. This is -11.3% lower than average price of previous purchases of PCRX. |
| KURA - Kura Oncology Inc | BUY | 150 @ USD 10.16 | USD 1,524 | The ETF bought 150 new shares of KURA (Kura Oncology Inc). The shares were bought for an average price of 10.16 compared to the previous average buy price of 7.15552. This is 42.0% higher than average price of previous purchases of KURA. |
| DAWN - Day One Biopharmaceuticals Inc | BUY | 168 @ USD 8.99 | USD 1,510 | The ETF bought 168 new shares of DAWN (Day One Biopharmaceuticals Inc). The shares were bought for an average price of 8.99 compared to the previous average buy price of 7.37094. This is 22.0% higher than average price of previous purchases of DAWN. |
| TNGX - Tango Therapeutics Inc | BUY | 184 @ USD 8.01 | USD 1,474 | The ETF bought 184 new shares of TNGX (Tango Therapeutics Inc). The shares were bought for an average price of 8.01 compared to the previous average buy price of 6.10436. This is 31.2% higher than average price of previous purchases of TNGX. |
| MNMD - Mind Medicine Inc | BUY | 128 @ USD 11.34 | USD 1,452 | The ETF bought 128 new shares of MNMD (Mind Medicine Inc). The shares were bought for an average price of 11.34 compared to the previous average buy price of 8.49523. This is 33.5% higher than average price of previous purchases of MNMD. |
| ABUS - Arbutus Biopharma Corp | BUY | 324 @ USD 4.44 | USD 1,439 | The ETF bought 324 new shares of ABUS (Arbutus Biopharma Corp). The shares were bought for an average price of 4.44 compared to the previous average buy price of 3.60358. This is 23.2% higher than average price of previous purchases of ABUS. |
| PAHC - Phibro Animal Health Corporation | BUY | 33 @ USD 43.04 | USD 1,420 | The ETF bought 33 new shares of PAHC (Phibro Animal Health Corporation). The shares were bought for an average price of 43.04 compared to the previous average buy price of 28.2482. This is 52.4% higher than average price of previous purchases of PAHC. |
| SPRY - Silverback Therapeutics Inc | BUY | 162 @ USD 8.195 | USD 1,328 | The ETF bought 162 new shares of SPRY (Silverback Therapeutics Inc). The shares were bought for an average price of 8.195 compared to the previous average buy price of 13.9065. This is -41.1% lower than average price of previous purchases of SPRY. |
| EYPT - Eyepoint Pharmaceuticals Inc | BUY | 114 @ USD 11.08 | USD 1,263 | The ETF bought 114 new shares of EYPT (Eyepoint Pharmaceuticals Inc). The shares were bought for an average price of 11.08 compared to the previous average buy price of 8.68404. This is 27.6% higher than average price of previous purchases of EYPT. |
| TBPH - Theravance Biopharma Inc | BUY | 83 @ USD 14.87 | USD 1,234 | The ETF bought 83 new shares of TBPH (Theravance Biopharma Inc). The shares were bought for an average price of 14.87 compared to the previous average buy price of 11.6119. This is 28.1% higher than average price of previous purchases of TBPH. |
| PRME - Prime Medicine, Inc. Common Stock | BUY | 291 @ USD 4.18 | USD 1,216 | The ETF bought 291 new shares of PRME (Prime Medicine, Inc. Common Stock). The shares were bought for an average price of 4.18 compared to the previous average buy price of 4.56417. This is -8.4% lower than average price of previous purchases of PRME. |
| ARVN - Arvinas Inc | BUY | 119 @ USD 10 | USD 1,190 | The ETF bought 119 new shares of ARVN (Arvinas Inc). The shares were bought for an average price of 10 compared to the previous average buy price of 8.69691. This is 15.0% higher than average price of previous purchases of ARVN. |
| VIR - Vir Biotechnology Inc | BUY | 229 @ USD 5.12 | USD 1,172 | The ETF bought 229 new shares of VIR (Vir Biotechnology Inc). The shares were bought for an average price of 5.12 compared to the previous average buy price of 5.84108. This is -12.3% lower than average price of previous purchases of VIR. |
| VIR - Vidrala S.A | BUY | 229 @ USD 5.12 | USD 1,172 | The ETF bought 229 new shares of VIR (Vidrala S.A). The shares were bought for an average price of 5.12 compared to the previous average buy price of 5.84108. This is -12.3% lower than average price of previous purchases of VIR. |
| SVRA - Savara Inc | BUY | 286 @ USD 3.98 | USD 1,138 | The ETF bought 286 new shares of SVRA (Savara Inc). The shares were bought for an average price of 3.98 compared to the previous average buy price of 2.75495. This is 44.5% higher than average price of previous purchases of SVRA. |
| GERN - Geron Corporation | BUY | 1,052 @ USD 1.08 | USD 1,136 | The ETF bought 1052 new shares of GERN (Geron Corporation). The shares were bought for an average price of 1.08 compared to the previous average buy price of 1.51743. This is -28.8% lower than average price of previous purchases of GERN. |
| ERAS - Erasca Inc | BUY | 506 @ USD 2.24 | USD 1,133 | The ETF bought 506 new shares of ERAS (Erasca Inc). The shares were bought for an average price of 2.24 compared to the previous average buy price of 1.62905. This is 37.5% higher than average price of previous purchases of ERAS. |
| REPL - Replimune Group Inc | BUY | 133 @ USD 8.50001 | USD 1,131 | The ETF bought 133 new shares of REPL (Replimune Group Inc). The shares were bought for an average price of 8.50001 compared to the previous average buy price of 8.8653. This is -4.1% lower than average price of previous purchases of REPL. |
| MGTX - MeiraGTx Holdings PLC | BUY | 134 @ USD 8.41 | USD 1,127 | The ETF bought 134 new shares of MGTX (MeiraGTx Holdings PLC). The shares were bought for an average price of 8.41 compared to the previous average buy price of 7.19461. This is 16.9% higher than average price of previous purchases of MGTX. |
| KROS - Keros Therapeutics Inc | BUY | 66 @ USD 16.17 | USD 1,067 | The ETF bought 66 new shares of KROS (Keros Therapeutics Inc). The shares were bought for an average price of 16.17 compared to the previous average buy price of 13.651. This is 18.5% higher than average price of previous purchases of KROS. |
| AVXL - Anavex Life Sciences Corp | BUY | 143 @ USD 7.4 | USD 1,058 | The ETF bought 143 new shares of AVXL (Anavex Life Sciences Corp). The shares were bought for an average price of 7.4 compared to the previous average buy price of 9.62281. This is -23.1% lower than average price of previous purchases of AVXL. |
| RGNX - Regenxbio Inc | BUY | 87 @ USD 11.17 | USD 972 | The ETF bought 87 new shares of RGNX (Regenxbio Inc). The shares were bought for an average price of 11.17 compared to the previous average buy price of 9.09605. This is 22.8% higher than average price of previous purchases of RGNX. |
| SIGA - SIGA Technologies Inc | BUY | 117 @ USD 8.16999 | USD 956 | The ETF bought 117 new shares of SIGA (SIGA Technologies Inc). The shares were bought for an average price of 8.16999 compared to the previous average buy price of 6.81697. This is 19.8% higher than average price of previous purchases of SIGA. |
| PACB - Pacific Biosciences of California | BUY | 529 @ USD 1.78 | USD 942 | The ETF bought 529 new shares of PACB (Pacific Biosciences of California). The shares were bought for an average price of 1.78 compared to the previous average buy price of 1.53911. This is 15.7% higher than average price of previous purchases of PACB. |
| PRTA - Prothena Corporation plc | BUY | 91 @ USD 10.08 | USD 917 | The ETF bought 91 new shares of PRTA (Prothena Corporation plc). The shares were bought for an average price of 10.08 compared to the previous average buy price of 8.94425. This is 12.7% higher than average price of previous purchases of PRTA. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 112 @ USD 8.18999 | USD 917 | The ETF bought 112 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 8.18999 compared to the previous average buy price of 5.46621. This is 49.8% higher than average price of previous purchases of OLMA. |
| FDMT - 4D Molecular Therapeutics Inc | BUY | 83 @ USD 10.92 | USD 906 | The ETF bought 83 new shares of FDMT (4D Molecular Therapeutics Inc). The shares were bought for an average price of 10.92 compared to the previous average buy price of 6.10392. This is 78.9% higher than average price of previous purchases of FDMT. |
| LXRX - Lexicon Pharmaceuticals Inc | BUY | 633 @ USD 1.43 | USD 905 | The ETF bought 633 new shares of LXRX (Lexicon Pharmaceuticals Inc). The shares were bought for an average price of 1.43 compared to the previous average buy price of 1.03389. This is 38.3% higher than average price of previous purchases of LXRX. |
| KALV - Kalvista Pharmaceuticals Inc | BUY | 82 @ USD 10.89 | USD 893 | The ETF bought 82 new shares of KALV (Kalvista Pharmaceuticals Inc). The shares were bought for an average price of 10.89 compared to the previous average buy price of 12.3583. This is -11.9% lower than average price of previous purchases of KALV. |
| EOLS - Evolus Inc | BUY | 117 @ USD 7.18 | USD 840 | The ETF bought 117 new shares of EOLS (Evolus Inc). The shares were bought for an average price of 7.18 compared to the previous average buy price of 9.25019. This is -22.4% lower than average price of previous purchases of EOLS. |
| HCM - HUTCHMED China Ltd | BUY | 53 @ USD 15.45 | USD 819 | The ETF bought 53 new shares of HCM (HUTCHMED China Ltd). The shares were bought for an average price of 15.45 compared to the previous average buy price of 15.5106. This is -0.4% lower than average price of previous purchases of HCM. |
| HCM - Hitachi Construction Machinery Co. Ltd | BUY | 53 @ USD 15.45 | USD 819 | The ETF bought 53 new shares of HCM (Hitachi Construction Machinery Co. Ltd). The shares were bought for an average price of 15.45 compared to the previous average buy price of 15.5106. This is -0.4% lower than average price of previous purchases of HCM. |
| GLPG - Galapagos NV ADR | BUY | 25 @ USD 31.2 | USD 780 | The ETF bought 25 new shares of GLPG (Galapagos NV ADR). The shares were bought for an average price of 31.2 compared to the previous average buy price of 29.0975. This is 7.2% higher than average price of previous purchases of GLPG. |
| GLPG - Galapagos N.V. | BUY | 25 @ USD 31.2 | USD 780 | The ETF bought 25 new shares of GLPG (Galapagos N.V.). The shares were bought for an average price of 31.2 compared to the previous average buy price of 29.0975. This is 7.2% higher than average price of previous purchases of GLPG. |
| MRVI - Maravai Lifesciences Holdings Inc | BUY | 262 @ USD 2.89 | USD 757 | The ETF bought 262 new shares of MRVI (Maravai Lifesciences Holdings Inc). The shares were bought for an average price of 2.89 compared to the previous average buy price of 2.68965. This is 7.4% higher than average price of previous purchases of MRVI. |
| CGEM - Cullinan Oncology LLC | BUY | 102 @ USD 7.35 | USD 750 | The ETF bought 102 new shares of CGEM (Cullinan Oncology LLC). The shares were bought for an average price of 7.35 compared to the previous average buy price of 7.86505. This is -6.5% lower than average price of previous purchases of CGEM. |
| ACIU - AC Immune Ltd | BUY | 169 @ USD 3.44999 | USD 583 | The ETF bought 169 new shares of ACIU (AC Immune Ltd). The shares were bought for an average price of 3.44999 compared to the previous average buy price of 2.36395. This is 45.9% higher than average price of previous purchases of ACIU. |
| RCKT - Rocket Pharmaceuticals Inc | BUY | 180 @ USD 3.22999 | USD 581 | The ETF bought 180 new shares of RCKT (Rocket Pharmaceuticals Inc). The shares were bought for an average price of 3.22999 compared to the previous average buy price of 5.1648. This is -37.5% lower than average price of previous purchases of RCKT. |
| LYEL - Lyell Immunopharma Inc | BUY | 32 @ USD 17.88 | USD 572 | The ETF bought 32 new shares of LYEL (Lyell Immunopharma Inc). The shares were bought for an average price of 17.88 compared to the previous average buy price of 6.286. This is 184.4% higher than average price of previous purchases of LYEL. |
| ALT - Altitude Group Plc | BUY | 144 @ USD 3.94001 | USD 567 | The ETF bought 144 new shares of ALT (Altitude Group Plc). The shares were bought for an average price of 3.94001 compared to the previous average buy price of 5.20689. This is -24.3% lower than average price of previous purchases of ALT. |
| IRWD - Ironwood Pharmaceuticals Inc | BUY | 259 @ USD 2.05 | USD 531 | The ETF bought 259 new shares of IRWD (Ironwood Pharmaceuticals Inc). The shares were bought for an average price of 2.05 compared to the previous average buy price of 1.11153. This is 84.4% higher than average price of previous purchases of IRWD. |
| BCYC - Bicycle Therapeutics Ltd | BUY | 80 @ USD 6.51001 | USD 521 | The ETF bought 80 new shares of BCYC (Bicycle Therapeutics Ltd). The shares were bought for an average price of 6.51001 compared to the previous average buy price of 8.60581. This is -24.4% lower than average price of previous purchases of BCYC. |
| AUTL - Autolus Therapeutics Ltd | BUY | 370 @ USD 1.36 | USD 503 | The ETF bought 370 new shares of AUTL (Autolus Therapeutics Ltd). The shares were bought for an average price of 1.36 compared to the previous average buy price of 1.86463. This is -27.1% lower than average price of previous purchases of AUTL. |
| VNDA - Vanda Pharmaceuticals Inc | BUY | 109 @ USD 4.40999 | USD 481 | The ETF bought 109 new shares of VNDA (Vanda Pharmaceuticals Inc). The shares were bought for an average price of 4.40999 compared to the previous average buy price of 4.86392. This is -9.3% lower than average price of previous purchases of VNDA. |
| TRDA - Entrada Therapeutics Inc | BUY | 69 @ USD 6.95 | USD 480 | The ETF bought 69 new shares of TRDA (Entrada Therapeutics Inc). The shares were bought for an average price of 6.95 compared to the previous average buy price of 7.628. This is -8.9% lower than average price of previous purchases of TRDA. |
| AVIR - Atea Pharmaceuticals Inc | BUY | 143 @ USD 3.25 | USD 465 | The ETF bought 143 new shares of AVIR (Atea Pharmaceuticals Inc). The shares were bought for an average price of 3.25 compared to the previous average buy price of 3.34458. This is -2.8% lower than average price of previous purchases of AVIR. |
| EDIT - Editas Medicine Inc | BUY | 164 @ USD 2.69001 | USD 441 | The ETF bought 164 new shares of EDIT (Editas Medicine Inc). The shares were bought for an average price of 2.69001 compared to the previous average buy price of 2.74658. This is -2.1% lower than average price of previous purchases of EDIT. |
| ARCT - Arcturus Therapeutics Holdings Inc | BUY | 48 @ USD 8.29 | USD 398 | The ETF bought 48 new shares of ARCT (Arcturus Therapeutics Holdings Inc). The shares were bought for an average price of 8.29 compared to the previous average buy price of 14.7591. This is -43.8% lower than average price of previous purchases of ARCT. |
| ALLO - Allogene Therapeutics Inc | BUY | 376 @ USD 1.05 | USD 395 | The ETF bought 376 new shares of ALLO (Allogene Therapeutics Inc). The shares were bought for an average price of 1.05 compared to the previous average buy price of 1.33658. This is -21.4% lower than average price of previous purchases of ALLO. |
| VYGR - Voyager Therapeutics Inc | BUY | 88 @ USD 4.21999 | USD 371 | The ETF bought 88 new shares of VYGR (Voyager Therapeutics Inc). The shares were bought for an average price of 4.21999 compared to the previous average buy price of 3.83344. This is 10.1% higher than average price of previous purchases of VYGR. |
| HUMA - Humacyte Inc | BUY | 279 @ USD 1.31 | USD 365 | The ETF bought 279 new shares of HUMA (Humacyte Inc). The shares were bought for an average price of 1.31 compared to the previous average buy price of 2.23657. This is -41.4% lower than average price of previous purchases of HUMA. |
| OABI - OmniAb Inc. | BUY | 212 @ USD 1.38 | USD 293 | The ETF bought 212 new shares of OABI (OmniAb Inc.). The shares were bought for an average price of 1.38 compared to the previous average buy price of 1.92855. This is -28.4% lower than average price of previous purchases of OABI. |
| MXCT - MaxCyte Inc | BUY | 184 @ USD 1.47 | USD 270 | The ETF bought 184 new shares of MXCT (MaxCyte Inc). The shares were bought for an average price of 1.47 compared to the previous average buy price of 2.20026. This is -33.2% lower than average price of previous purchases of MXCT. |
| ALEC - Alector Inc | BUY | 182 @ USD 1.3 | USD 237 | The ETF bought 182 new shares of ALEC (Alector Inc). The shares were bought for an average price of 1.3 compared to the previous average buy price of 1.94702. This is -33.2% lower than average price of previous purchases of ALEC. |
| FATE - Fate Therapeutics Inc | BUY | 187 @ USD 1.03999 | USD 194 | The ETF bought 187 new shares of FATE (Fate Therapeutics Inc). The shares were bought for an average price of 1.03999 compared to the previous average buy price of 1.1922. This is -12.8% lower than average price of previous purchases of FATE. |
| BMEA - Biomea Fusion Inc | BUY | 119 @ USD 1.29999 | USD 155 | The ETF bought 119 new shares of BMEA (Biomea Fusion Inc). The shares were bought for an average price of 1.29999 compared to the previous average buy price of 1.82435. This is -28.7% lower than average price of previous purchases of BMEA. |
| PLRX - Pliant Therapeutics Inc | BUY | 100 @ USD 1.52999 | USD 153 | The ETF bought 100 new shares of PLRX (Pliant Therapeutics Inc). The shares were bought for an average price of 1.52999 compared to the previous average buy price of 1.49082. This is 2.6% higher than average price of previous purchases of PLRX. |
| MGNX - MacroGenics Inc | BUY | 106 @ USD 1.35999 | USD 144 | The ETF bought 106 new shares of MGNX (MacroGenics Inc). The shares were bought for an average price of 1.35999 compared to the previous average buy price of 1.58108. This is -14.0% lower than average price of previous purchases of MGNX. |
| STRO - Sutro Biopharma | BUY | 135 @ USD 0.942199 | USD 127 | The ETF bought 135 new shares of STRO (Sutro Biopharma). The shares were bought for an average price of 0.942199 compared to the previous average buy price of 0.901103. This is 4.6% higher than average price of previous purchases of STRO. |
| OKUR - OKUR | BUY | 21 @ USD 3.16003 | USD 66 | The ETF bought 21 new shares of OKUR (OKUR). The shares were bought for an average price of 3.16003 compared to the previous average buy price of 6.12924. This is -48.4% lower than average price of previous purchases of OKUR. |
| MRSN - Mersana Therapeutics Inc | BUY | 8 @ USD 8.04001 | USD 64 | The ETF bought 8 new shares of MRSN (Mersana Therapeutics Inc). The shares were bought for an average price of 8.04001 compared to the previous average buy price of 0.526763. This is 1,426.3% higher than average price of previous purchases of MRSN. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.31 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.31. The average price that IOVA shares were previous bought at was USD 2.43787. The current market price is -5.2% lower than average price they were purchased at. The value of the holding in IOVA has increased by USD 113,337 compared to the previous valuation of Iovance Biotherapeutics Inc however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.06885. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| URGN - UroGen Pharma Ltd | HOLD | 0 @ USD 23.54 | USD 0 | The current share valuation price of URGN based on adjusted close was USD 23.54. The average price that URGN shares were previous bought at was USD 14.5512. The current market price is 61.8% higher than average price they were purchased at. The value of the holding in URGN has increased by USD 129,573 compared to the previous valuation of UroGen Pharma Ltd however if the holding was sold on 2025-11-06 this would crystalise an overall loss. |
| XERS - Xeris Pharmaceuticals Inc | HOLD | 0 @ USD 7.71 | USD 0 | The current share valuation price of XERS based on adjusted close was USD 7.71. The average price that XERS shares were previous bought at was USD 6.01947. The current market price is 28.1% higher than average price they were purchased at. The value of the holding in XERS has fallen by USD 229,578 compared to the previous valuation of Xeris Pharmaceuticals Inc |